Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib + vemurafenib in BRAF V600E metastatic colorectal cancer and lung cancer
ACTRN12614000486628Phase 2Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of erlotinib and vemurafenib in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) (4 arms), sponsored by Peter MacCallum Cancer Centre. Primary endpoints: Safety and determination of dosing regimen for phase II and Objective response rate in metastatic colorectal cancer. Started Jul 2014; status: completed.
02
Drugs
erlotinibvemurafenib
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12614000486628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000486628.